cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases

Kloster,Martine  Müller; Naderi,Elin  Hallan; Haaland,Ingvild; Gjertsen,Bjørn  Tore; Blomhoff,Heidi  Kiil; Naderi,Soheil

doi:10.3892/ijo.2013.1853

cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases

Authors:
- Martine Müller Kloster
- Elin Hallan Naderi
- Ingvild Haaland
- Bjørn Tore Gjertsen
- Heidi Kiil Blomhoff
- Soheil Naderi
View Affiliations

Affiliations: Institute of Basic Medical Sciences, University of Oslo, N-0317 Oslo, Norway, Institute of Medicine, Hematology Section, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway
Published online on: March 8, 2013 https://doi.org/10.3892/ijo.2013.1853
Pages: 1815-1821

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of cAMP signalling potently inhibits DNA damage-induced apoptosis in acute lymphoblastic leukemia cells by promoting the turnover of p53 protein. Recently, we showed that the cAMP-induced destabilization of p53 in DNA-damaged cells occurs as a result of enhanced interaction between p53 and HDM2. In this report, we present results showing that increased levels of cAMP in cells with DNA damage enhances the deacetylation of p53, an event that facilitates the interaction of p53 with HDM2, thus annulling the stabilizing effect of DNA damage on p53. The combined inhibition of the HDAC and SIRT1 deacetylases abolished the cAMP-mediated deacetylation of p53, implying that cAMP-mediated deacetylation of p53 is dependent on the activity of these two classes of histone deacetylases. Importantly, diminishing the activity of HDACs and SIRT1 was also found to reverse the inhibitory effect of cAMP on the DNA damage-induced p53 stabilization and apoptosis, suggesting the involvement of the p53 acetylation pathway in the anti-apoptotic effect of cAMP signalling.

View Figures

View References

1.	Dai C and Gu W: p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 16:528–536. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Appella E and Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 268:2764–2772. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Brooks CL and Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 15:164–171. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Brooks CL and Gu W: The impact of acetylation and deacetylation on the p53 pathway. Protein Cell. 2:456–462. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Li M, Luo J, Brooks CL and Gu W: Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem. 277:50607–50611. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD and Berger SL: p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 19:1202–1209. 1999.PubMed/NCBI
8.	Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
9.	Wang YH, Tsay YG, Tan BC, Lo WY and Lee SC: Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem. 278:25568–25576. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Tang Y, Zhao W, Chen Y, Zhao Y and Gu W: Acetylation is indispensable for p53 activation. Cell. 133:612–626. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Torgersen KM, Vang T, Abrahamsen H, Yaqub S and Tasken K: Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 14:1–9. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Blomhoff HK, Blomhoff R, Stokke T, deLange DC, Brevik K, Smeland EB, Funderud S and Godal T: cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1. J Cell Physiol. 137:583–587. 1988. View Article : Google Scholar : PubMed/NCBI
13.	Blomhoff HK, Smeland EB, Beiske K, Blomhoff R, Ruud E, Bjoro T, Pfeifer-Ohlsson S, Watt R, Funderud S and Godal T: Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes. J Cell Physiol. 131:426–433. 1987. View Article : Google Scholar : PubMed/NCBI
14.	Naderi S, Gutzkow KB, Christoffersen J, Smeland EB and Blomhoff HK: cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of cyclin D3 at the level of translation. Eur J Immunol. 30:1757–1768. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Naderi S, Wang JY, Chen TT, Gutzkow KB and Blomhoff HK: cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA. Mol Biol Cell. 16:1527–1542. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Naderi EH, Findley HW, Ruud E, Blomhoff HK and Naderi S: Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood. 114:608–618. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Naderi EH, Jochemsen AG, Blomhoff HK and Naderi S: Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2. Neoplasia. 13:653–663. 2011.PubMed/NCBI
18.	Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, Pico JL and Greaves MF: Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 267:841–843. 1977. View Article : Google Scholar : PubMed/NCBI
19.	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
20.	Cai R, Kwon P, Yan-Neale Y, Sambuccetti L, Fischer D and Cohen D: Mammalian histone deacetylase 1 protein is post-translationally modified by phosphorylation. Biochem Biophys Res Commun. 283:445–453. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Du M, Perry RL, Nowacki NB, Gordon JW, Salma J, Zhao J, Aziz A, Chan J, Siu KW and McDermott JC: Protein kinase A represses skeletal myogenesis by targeting myocyte enhancer factor 2D. Mol Cell Biol. 28:2952–2970. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Gerhart-Hines Z, Dominy JE Jr, Blattler SM, Jedrychowski MP, Banks AS, Lim JH, Chim H, Gygi SP and Puigserver P: The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell. 44:851–863. 2011.PubMed/NCBI
23.	Ha CH, Kim JY, Zhao J, Wang W, Jhun BS, Wong C and Jin ZG: PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 107:15467–15472. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Wang X, Taplick J, Geva N and Oren M: Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 561:195–201. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J and Gu W: Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 416:648–653. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Batty N, Malouf GG and Issa JP: Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 280:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI